Zacks Research Downgrades Phibro Animal Health (NASDAQ:PAHC) to Hold

Phibro Animal Health (NASDAQ:PAHC) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $3.04 EPS, Q2 2027 earnings at $0.84 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $0.80 EPS, FY2027 earnings at $3.17 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $0.91 EPS, Q3 2028 earnings at $0.81 EPS and FY2028 earnings at $3.34 EPS.

PAHC has been the subject of several other research reports. Citigroup reduced their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. Finally, Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Stock Down 0.6%

Shares of NASDAQ:PAHC opened at $33.26 on Thursday. The company has a market capitalization of $1.35 billion, a PE ratio of 14.27, a P/E/G ratio of 0.51 and a beta of 0.61. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a twelve month low of $22.51 and a twelve month high of $60.08. The firm has a 50 day simple moving average of $50.29 and a 200-day simple moving average of $45.99.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities analysts predict that Phibro Animal Health will post 3.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 4,528 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the sale, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. This represents a 7.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 89,008 shares of company stock valued at $4,757,177. 50.13% of the stock is owned by corporate insiders.

Institutional Trading of Phibro Animal Health

Several institutional investors and hedge funds have recently bought and sold shares of PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the last quarter. Millennium Management LLC raised its position in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the last quarter. Jane Street Group LLC raised its position in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after purchasing an additional 13,404 shares during the last quarter. Cetera Investment Advisers increased its stake in Phibro Animal Health by 63.0% in the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock valued at $481,000 after buying an additional 7,280 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Phibro Animal Health by 2.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after buying an additional 363 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised its earnings estimates for multiple future periods, including FY2026, FY2027, and FY2028, while reiterating a Strong-Buy rating on Phibro Animal Health (NASDAQ:PAHC), which could support sentiment around the stock.
• Neutral Sentiment: Phibro announced it will participate in the Stifel Jaws & Paws Conference on May 27, giving management another opportunity to discuss strategy and outlook with investors. Article Title
• Negative Sentiment: Despite the upgraded earnings forecasts, the stock is still facing pressure from a Citi price-target cut to $44 from $62 earlier in the week, which may be weighing on shares and signaling concerns about sector conditions. Article Title

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.